N I Nissen

Author PubWeight™ 70.26‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 1983 6.38
2 Standardization of high-resolution flow cytometric DNA analysis by the simultaneous use of chicken and trout red blood cells as internal reference standards. Cytometry 1983 2.32
3 Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. Blood 1981 1.68
4 Limits of detection of nuclear DNA abnormalities by flow cytometric DNA analysis. Results obtained by a set of methods for sample-storage, staining and internal standardization. Cytometry 1983 1.56
5 Long-term storage of samples for flow cytometric DNA analysis. Cytometry 1983 1.36
6 Acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome secondary to treatment of other malignant diseases. II. Bone marrow cytology, cytogenetics, results of HLA typing, response to antileukemic chemotherapy, and survival in a total series of 55 patients. Cancer 1984 1.21
7 Treatment of small-cell carcinoma of the lung monitored by sequential flow cytometric DNA analysis. Cancer Res 1982 1.18
8 Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy. Lancet 1987 1.15
9 Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents. Ann Intern Med 1985 1.09
10 Clonal heterogeneity of small-cell anaplastic carcinoma of the lung demonstrated by flow-cytometric DNA analysis. Cancer Res 1980 1.05
11 Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. Acta Pathol Microbiol Scand A 1973 1.02
12 A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas. Cancer 1983 1.02
13 Membrane transport of anthracyclines. Pharmacol Ther 1982 1.00
14 Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 1988 0.99
15 Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF. Eur J Clin Invest 1992 0.98
16 Follicular low-grade non-Hodgkin's lymphoma: long-term outcome with or without tumor progression. Eur J Haematol 1989 0.98
17 Lymphoblastic lymphoma: a clinicopathologic study of 95 patients. Cancer 1981 0.94
18 Mechanism of resistance to anthracyclines and vinca alkaloids. Prog Clin Biol Res 1983 0.93
19 Combination chemotherapy and radiotherapy for acute lymphocytic leukemia in adults: results of CALGB protocol 7113. Leuk Res 1979 0.91
20 Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment. Cancer 1988 0.91
21 Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle. Cancer Treat Rev 1984 0.89
22 Acute non-lymphocytic leukemia in patients with ovarian carcinoma following long-term treatment with Treosulfan (= dihydroxybusulfan). Cancer 1980 0.89
23 Effect of verapamil on daunorubicin accumulation in Ehrlich ascites tumor cells. Cancer Chemother Pharmacol 1987 0.88
24 Synchronization of the human promyelocytic cell line HL 60 by thymidine. Cell Tissue Kinet 1986 0.87
25 Meningeal involvement in non-Hodgkin's lymphoma: symptoms, incidence, risk factors and treatment. Scand J Haematol 1985 0.86
26 PHASE I clinical trial of an oral solution of VP-16-213. Cancer Treat Rep 1976 0.84
27 Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors. Cancer Chemother Rep 1972 0.83
28 Occurrence of human T cell lymphotropic virus (type I) antibodies in cutaneous T cell lymphoma. J Am Acad Dermatol 1986 0.83
29 Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother Pharmacol 1992 0.83
30 Radiotherapy versus combined modality treatment of stage I and II Hodgkin's disease. Cancer Treat Rep 1982 0.83
31 Thyroid function in malignant lymphoma. Acta Med Scand 1977 0.83
32 Comparative pharmacokinetics of single-dose administration of mammalian and bacterially-derived recombinant human granulocyte-macrophage colony-stimulating factor. Eur J Haematol 1993 0.82
33 Fatal hepatitis following irradiation and vincristine. Acta Med Scand 1982 0.82
34 A phase I/II study of dose and administration of non-glycosylated bacterially synthesized G-M CSF in chemotherapy-induced neutropenia in patients with non-Hodgkin's lymphomas. Leuk Lymphoma 1992 0.81
35 The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review. Recent Results Cancer Res 1980 0.81
36 Effect of age on therapeutic response and survival in advanced Hodgkin's disease. Cancer Treat Rep 1982 0.81
37 Clinical trial with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep 1972 0.81
38 Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy. A prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol 1986 0.80
39 Immunohistochemical identification of lymphocyte subsets and accessory cells in human hyperplastic lymph nodes. The functional significance of the compartmentalization of lymphoid tissue. Scand J Haematol 1984 0.80
40 Abolished production of interferon by leucocytes of patients with the acquired cytogenetic abnormalities 5q -- or -- 5 in secondary and de-novo acute non-lymphocytic leukaemia. Br J Haematol 1980 0.80
41 Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. Cancer Treat Rep 1982 0.80
42 Anticoagulant treatment of acute coronary thrombosis. Acta Med Scand 1969 0.80
43 Prognostic significance of tumour burden in Hodgkin's disease PS I and II. Scand J Haematol 1986 0.79
44 Metabolic studies in man with mycophenolic acid (NSC-129185), a new antitumor agent. Cancer Chemother Rep 1972 0.79
45 Prognostic factors in Hodgkin's disease stage IV. Eur J Haematol 1988 0.79
46 Daunorubicin in the therapy of acute granulocytic leukemia. Cancer Res 1973 0.79
47 Clinical experience with bacteraemia in patients with leukaemia and allied neoplastic diseases. Chemotherapy 1978 0.78
48 Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer 1993 0.78
49 Anthracycline resistance. Acta Oncol 1989 0.78
50 Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells. Br J Cancer 1993 0.78
51 Cefotaxime versus ampicillin, methicillin and netilmicin in combination for treatment of febrile episodes in patients with haematologic malignancy. Acta Med Scand 1983 0.78
52 Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial. Cancer Treat Rep 1984 0.78
53 Changes over the course of time in histological subclassification of Hodgkin's disease in Denmark. Dan Med Bull 1991 0.78
54 Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease. Scand J Haematol 1985 0.77
55 Overview of four clinical studies of chemotherapy for stage III and IV non-Hodgkin's lymphomas by the Cancer and Leukemia Group B. Cancer Treat Rep 1977 0.77
56 Comparison of the working formulation of non-Hodgkin's lymphoma with the Rappaport, Kiel, and Lukes & Collins classifications. Translational value and prognostic significance based on review of 658 patients treated at a single institution. Cancer 1985 0.77
57 Human immunodeficiency virus (HIV) associated non-Hodgkin's lymphomas in Denmark: report of three cases. Eur J Haematol 1987 0.77
58 A simplified working formulation of non-Hodgkin's lymphomas based on quantifiable histologic criteria. Cancer 1989 0.77
59 Phase I trial of a new form of an oral administration of VP-16-213. Cancer Treat Rep 1979 0.77
60 A comparative study of a BCNU containing 4-drug program versus MOPP versus 3-drug combinations in advanced Hodgkin's disease: a cooperative study by the Cancer and Leukemia Group B. Cancer 1979 0.77
61 The liver in Hodgkin's disease--II. Histopathologic findings. Eur J Cancer Clin Oncol 1982 0.77
62 In vitro circumvention of anthracycline--resistance in Ehrlich ascites tumour by anthracycline analogues. Biochem Pharmacol 1990 0.77
63 Modulation of neutrophil and monocyte function by recombinant human granulocyte macrophage colony-stimulating factor in patients with lymphoma. Eur J Clin Invest 1991 0.77
64 Development and application of a sensitive radioimmunoassay for human granulocyte-macrophage colony-stimulating factor able to measure normal concentrations in blood. Exp Hematol 1993 0.77
65 A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer 1980 0.77
66 In vivo kinetics of 111indium-labelled autologous granulocytes following i.v. administration of granulocyte-macrophage colony-stimulating factor (GM-CSF). Eur J Haematol 1992 0.77
67 Clonal evolution demonstrated by flow cytometric DNA analysis of a human colonic carcinoma grown in nude mice. Exp Cell Biol 1982 0.77
68 Cross resistance and cellular uptake of 4'-O-methyldoxorubicin in experimental tumors with acquired resistance to doxorubicin. Cancer Chemother Pharmacol 1981 0.76
69 Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B. Cancer 1980 0.76
70 Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213). Cancer Chemother Rep 1972 0.76
71 Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B. Cancer 1981 0.76
72 Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma. Cancer 1978 0.76
73 Cefotaxime monotherapy in septicemic patients with hematological malignancies. Clin Ther 1986 0.75
74 Effect of methanol extraction residue of Bacillus Calmette-Guerin in advanced Hodgkin's disease. Cancer 1982 0.75
75 Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy. Br J Cancer 1987 0.75
76 Phase II trial of cis-dichlorodiammineplatinum(II) in advanced malignant lymphoma and small cell lung cancer: preliminary results. Cancer Treat Rep 1980 0.75
77 Ornithine carbamoyl transferase activity in serum. Preliminary experience with a non-isotopic method suitable for routine clinical analysis. Scand J Clin Lab Invest Suppl 1967 0.75
78 Management of non-Hodgkin lymphoma in adults in Scandinavia, United Kingdom, and The Netherlands. Report from the European School of Oncology intercity meeting at Huddinge Hospital, 3rd June, 1988. Acta Oncol 1989 0.75
79 [Effect of a mineral preparation on transplanted mouse tumours]. Ugeskr Laeger 1975 0.75
80 In vitro stimulation of human neutrophil granulopoiesis by unmasking an effect of human serum. Target cell specificity. Scand J Haematol 1983 0.75
81 Expression of an antigen defined by a monoclonal antibody (SA-1) on normal and malignant cells. Scand J Haematol 1985 0.75
82 Increased uptake of actinomycin D in Ehrlich ascites tumour cells induced by daunorubicin. Cancer Chemother Pharmacol 1983 0.75
83 The in vivo effects of interleukin-3 on histamine levels in non-Hodgkin's lymphoma patients. Pharmacol Toxicol 1997 0.75
84 [Malignant hematologic diseases. Diagnosis and treatment. A clearing report]. Ugeskr Laeger 1991 0.75
85 Comparative studies on spironolactone (Aldactone) and chlorthalidone (Hygroton) in the treatment of arterial hypertension. Acta Med Scand 1966 0.75
86 Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents. Acta Med Scand 1980 0.75
87 The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. Cancer 1981 0.75
88 Automated cytochemistry in the prediction of remission following chemotherapy of patients with de novo acute myeloblastic leukemia. Am J Clin Pathol 1982 0.75
89 Therapy-related acute nonlymphocytic leukemia of FAB type M4 or M5 with early onset and t(9;11) (p21;q23) or a normal karyotype: a separate entity? J Clin Oncol 1988 0.75
90 Radiographic evaluation of pulmonary fibrosis following mantle field irradiation in Hodgkin's disease. Acta Radiol Oncol 1986 0.75
91 [Lactate dehydrogenase isoenzyme patterns in serum in hematologic and neoplastic diseases]. Nord Med 1968 0.75
92 [Ultrasound and lymphography in malignant lymphoma. Comparison with consideration to staging]. Ugeskr Laeger 1994 0.75
93 Clinical trial of the oral form of a new podophyllotoxin derivative, VP-16-213 (NSC-141540), in patients with advanced neoplastic disease. Cancer Chemother Rep 1976 0.75
94 Chemotherapy with or without radiotherapy in malignant lymphomas. Antibiot Chemother (1971) 1978 0.75
95 High-risk AML evidenced by a monoclonal antibody. Eur J Haematol 1988 0.75
96 Effects of interleukin-3 following chemotherapy of non-Hodgkin's lymphoma. A prospective, controlled phase I/II study. Eur J Haematol 1995 0.75
97 Chemotherapy of Hodgkin's disease in studies by acute leukemia group B. Arch Intern Med 1973 0.75
98 VP-16-213 in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in the treatment of non-Hodgkin's lymphomas. Cancer Treat Rep 1981 0.75
99 Hodgkin's disease and age. Eur J Haematol 1989 0.75
100 [Estrogen therapy of prostatic cancer. 76 cases of previously undiagnosed prostatic cancer treated with F6066 (bis-(p-acetoxyphenyl)cyclohexylidenemethane) and diethylstilbestrol--a double-blind study]. Nord Med 1969 0.75
101 The relative merit of various cytochemical quantities and manual differential count in predicting remission following chemotherapy of patients with de novo acute myeloblastic leukemia. Am J Clin Pathol 1985 0.75
102 The liver in Hodgkin's disease--I. Clinico-pathological relations. Eur J Cancer Clin Oncol 1982 0.75
103 Hodgkin's disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavourable combination. Eur J Haematol 1988 0.75
104 Influence of age and duration of follow-up on lung function after combined chemotherapy for Hodgkin's disease. Eur Respir J 1990 0.75
105 High activity of mitoxantrone in previously untreated low-grade lymphomas. Cancer Chemother Pharmacol 1988 0.75
106 [Serum-lactate dehydrogenase isoenzymes in myocardial and hepatic disease]. Nord Med 1967 0.75
107 Bacteremia and candidemia in hematological malignancies: clinical findings. Scand J Infect Dis 1988 0.75
108 Experiences from the National Danish Hodgkin's Study Group (LYGRA) with respect to diagnosis, classification and treatment of Hodgkin's disease. Acta Radiol Oncol 1984 0.75
109 [Rubidomycin-daunomycin therapy in acute myeloblastic leukemia]. Nord Med 1968 0.75
110 Micropore filters for sterile filtration may leach toxic compounds affecting cell cultures (HL 60). Exp Hematol 1985 0.75
111 Clinical trial of rubidazone in solid tumors and malignant lymphomas. Cancer Treat Rep 1978 0.75
112 [Acute non-lymphocytic leukemia (ANLL) in adults. Therapeutic criteria and their consequences]. Ugeskr Laeger 1988 0.75
113 [Chronic lymphocytic leukemia treated with herbal remedy consisting of plant extracts]. Ugeskr Laeger 1979 0.75
114 [Clinically controlled research in tumor chemotherapy]. Nord Med 1971 0.75
115 Oral idarubicin in elderly patients with acute myeloid leukemia. Eur J Haematol 1990 0.75
116 Toxicity of intravenous catheters tested in a human bone marrow culture system. Acta Med Scand 1977 0.75
117 Bacteraemia in patients with leukaemia and allied neoplastic diseases. Scand J Infect Dis 1976 0.75
118 Leukemia following treatment of germ cell tumors in men. J Clin Oncol 1985 0.75
119 Predictive value of bone marrow cultures in 48 patients with acute myeloblastic leukaemia or myelodysplasia both secondary to treatment of other malignant diseases. Scand J Haematol 1985 0.75
120 [Drug treatment of neoplastic diseases]. Nord Med 1966 0.75
121 Immunological markers in acute leukaemia. Scand J Haematol 1985 0.75
122 Tumor cell concentration and tumor burden in relation to histopathologic subtype and other prognostic factors in early stage Hodgkin's disease. The Danish National Hodgkin Study Group. Cancer 1990 0.75
123 [Hodgkin's disease and other malignant lymphomas]. Ugeskr Laeger 1972 0.75
124 [Vinblastine in the treatment of Hodgkin's disease]. Nord Med 1971 0.75
125 [New principles of treatment in acute leukemia]. Ugeskr Laeger 1970 0.75
126 Naproxen has greater antipyretic effect on Hodgkin's disease-related fever than no other tumours or infection. Scand J Haematol 1985 0.75
127 Comparative studies on the diuretic and biochemical effects of prednisone and spironolactone in hepatic cirrhosis. Acta Med Scand 1966 0.75
128 Combination chemotherapy of non-Hodgkin lymphoma. Med Pediatr Oncol 1978 0.75
129 Studies on the antineoplastic effect of vanadium salts. Acta Chir Scand Suppl 1965 0.75
130 [Thyroid function in malignant lymphoma]. Ugeskr Laeger 1977 0.75
131 [Phase-II-study with cis-diamminedichloroplatinum (II) in the treatment of advanced malignant lymphomas]. Schweiz Med Wochenschr 1980 0.75
132 [Serious side-effects following treatment with mistletoe extract]. Ugeskr Laeger 1983 0.75
133 Severe aplastic anaemia with complete autologous marrow reconstitution following treatment with antithymocyte globulin. Report of a case and review of the literature. Scand J Haematol 1978 0.75
134 Non-Hodgkin malignant lymphomas and Hodgkin's disease in first-degree relatives. Evidence for a mutual genetic predisposition? Scand J Haematol 1986 0.75
135 Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study. J Clin Oncol 1992 0.75
136 Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma. Br J Haematol 1995 0.75
137 [Solid tumors in childhood. With special reference to cytostatic treatment]. Ugeskr Laeger 1978 0.75
138 Long term follow-up of combination chemotherapy-radiotherapy of stage III Hodgkin's disease: a Cancer and Acute Leukemia Group B study. Cancer 1979 0.75
139 Combination chemotherapy for non-Hodgkin lymphomas: a ten year follow-up study. Med Pediatr Oncol 1979 0.75
140 [Medical treatment of cancer--an elucidating report]. Ugeskr Laeger 1988 0.75
141 Mitoxantrone in the treatment of chronic lymphocytic leukemia. Leuk Lymphoma 1992 0.75
142 [Evaluation of the clinical effect of antineoplastic drugs]. Ugeskr Laeger 1972 0.75
143 [Vincristine sulfas (Oncovin), a cytostatic agent]. Ugeskr Laeger 1973 0.75
144 [Allopurinol treatment of hyperuricemia]. Nord Med 1967 0.75
145 Patterns of lactic acid dehydrogenase isoenzymes in normal and malignant human tissues. Eur J Cancer 1965 0.75
146 [Letter: The anti-neoplastic effect of Scanalka]. Ugeskr Laeger 1976 0.75
147 Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden. Eur J Haematol 1988 0.75
148 [Bone marrow biopsy with Radner's needle. A new method for bone marrow examination]. Ugeskr Laeger 1974 0.75
149 1 alpha(OH)D3 (ETALPHA) treatment and receptor studies in 16 patients with chronic and myeloproliferative disorders. Eur J Haematol 1987 0.75
150 Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia. Eur J Cancer 1976 0.75
151 The Radner needle a bone-marrow biopsy device. Scand J Haematol 1974 0.75
152 Human immunodeficiency virus (HIV) antibody testing in 862 patients with lymphoma and leukaemia attending a department of haematology (1984-1988) Eur J Haematol 1989 0.75
153 [Hodgkin's disease--a histologic problem]. Ugeskr Laeger 1989 0.75
154 Recombinant human interleukin-3: pharmacokinetics after intravenous and subcutaneous bolus injection and effects on granulocyte kinetics. Br J Haematol 1994 0.75
155 Radiotherapy versus radiotherapy plus chemotherapy in stages I and II Hodgkin's disease. A prospective, randomized study by the Danish National Hodgkin Study Group, LYGRA. Scand J Haematol 1980 0.75
156 S-phase induction by interleukin-6 followed by chemotherapy in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Leuk Lymphoma 1999 0.75
157 [Vinca alkaloids, a newer group of anti-neoplastic drugs]. Ugeskr Laeger 1972 0.75
158 [Use of chemotherapy in combination with surgery and irradiation in cases of nephroblastoma (Wilm's tumor)]. Ugeskr Laeger 1973 0.75
159 S-phase induction by interleukin-6 followed by chemotherapy in patients with refractory multiple myeloma. Leuk Res 1998 0.75
160 Late effects on pulmonary function of mantle-field irradiation, chemotherapy or combined modality therapy for Hodgkin's disease. Eur J Haematol 1990 0.75
161 [Rubidomycin-daunomycin, a new antibiotic with antineoplastic effect]. Nord Med 1968 0.75
162 Adriamycin, an antitumour antibiotic: a review with special reference to daunomycin. Dan Med Bull 1975 0.75
163 [Campath-1H--a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia]. Ugeskr Laeger 1997 0.75